Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, according to data presented at the American College of Allergy, Asthma & ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

Pfizer seals the deal with Metsera for $10 billion after Novo Nordisk bowed out; President Donald Trump welcomes executives ...

Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

S anofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

In recent days, Regeneron Pharmaceuticals announced detailed positive Phase 2 trial results for two novel factor XI ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Sanofi and Regeneron Pharmaceuticals said their jointly developed Dupixent anti-inflammatory blockbuster drug achieved primary and secondary goals in a late-stage study for allergic fungal ...